If you entered a web address please check it was correct.
\nYou can also try Search Page to find the study you are looking for.
"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"A unique number for a study given by ViiV.
"}},"ctGov":{"childMarkdownRemark":{"html":"This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.
"}},"eudraCT":{"childMarkdownRemark":{"html":"This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.
"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"","IsFlexibleTrial":false,"IsReleasedToCtGov":"false","MaskingInfo":{"masked_assessor":"false","masked_caregiver":"false","masked_investigator":"false","masked_subject":"false","masking_description":"","no_masking":""},"PatientLevelData":"false","SharingIpd":"","acronym":"","allocation":"","arm_groups":[{"arm_group_label":"Subjects treated with DTG","arm_group_description":"Subjects previously included in Spring 2, Single, Flamingo, Aria or Sailing studies and who were treated with DTG as part of combination ART (cART) will be included in this study.","arm_type":""},{"arm_group_label":"Subjects treated with non-DTG containing cART regimen","arm_group_description":"Subjects previously included in Spring 2, Single, Flamingo, Aria or Sailing studies and who were treated with non-DTG containing cART regimen will be included in this study.","arm_type":""},{"arm_group_label":"Subjects treated with DTG plus ABC","arm_group_description":"Subjects previously included in Spring 2, Single, Flamingo, Aria or Sailing studies and who were treated with DTG plus ABC regimen will be included in this study.","arm_type":""},{"arm_group_label":"Subjects treated with DTG plus other regimen","arm_group_description":"Subjects previously included in Spring 2, Single, Flamingo, Aria or Sailing studies and who were treated with DTG plus other regimen will be included in this study.","arm_type":""}],"assignment":"","brief_summary":"In treatment- naïve Phase III/IIIb trials of DTG compared with other anti-retroviral therapy (ART) regimen, CNS adverse events (AEs) rates were low. However, it was observed that CNS AEs may result in higher rates of DTG discontinuation in clinical practice than documented in clinical trials. Hence, this meta-analysis aims to re-examine data from the previously conducted phase III/IIIb adult naïve studies including Spring 2, Single, Flamingo and Aria as well as the adult experienced Sailing study to identify if there are any predictors of development of a CNS AE during the course of the trials. Data of subjects infected with human immunodeficiency virus (HIV) and treated with DTG containing versus non DTG containing regimens as well as DTG + Abacavir (ABC) exposure versus DTG + other regimens will be evaluated. The meta-analysis will include total 1672 subjects who were exposed to DTG; total 1681 subjects who were exposed to comparator regimen and total 930 subjects who were exposed to DTG + ABC containing regimen from all 5 studies.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"Dolutegravir Use and Predictors of CNS events: Meta-analysis of Data from Phase III/IIIb Clinical Trials","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"Infection, Human Immunodeficiency Virus","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 21:27:38","criteria":"Inclusion Criteria: - Adult subjects included in Spring 2, Single, Flamingo, Aria or Sailing studies. Exclusion Criteria: - Not applicable.","detailed_description":"","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"Phase 4","display_phase_internal":"PHASE_4","display_status":"Ongoing","display_status_internal":"RECSTATUS_O_ONGOING","endpoint":"","enrollment":"1","exclusion":"","gender":"Both","gender_based":"","gender_description":"","healthy_volunteers":"None","id":"9f8fbc52-568c-5c0c-a5bf-8ab13cfc7d69","internal":{"content":null,"contentDigest":"c0e5822a5ebd32676de246a16f9531e6","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria: - Adult subjects included in Spring 2, Single, Flamingo, Aria or Sailing studies. Exclusion Criteria: - Not applicable.","interventions":[],"interventional_subtype":"","is_fda_regulated":false,"is_high_value":false,"is_ind_study":false,"keywords":["Predictors","Meta-analysis","Dolutegravir","HIV","Central Nervous System events"],"last_follow_up_date":"04/27/2018 00:00:00","links":[],"locations":[],"masking":"","maximum_age_raw":"","maximum_age":null,"minimum_age":"18Years","minimum_age_raw":"18Years","modified_date":"10/01/2018 22:47:09","number_of_arms":"0","observational_design":{"biospecimen_description":"NA","biospecimen_retention":"None retained","number_of_groups":"0","observational_study_design":"Cohort","patient_registry":"false","target_duration_quantity":"","target_duration_units":"","timing":"Retrospective"},"official_title":"Dolutegravir Use and Predictors of CNS events: Meta-analysis of Data from Phase III/IIIb Clinical Trials","org_study_id":"207953","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Active, not recruiting - Observational","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"Phase 4","primary_compl_date":"12/29/2017 00:00:00","primary_outcomes":[{"outcome_description":"","outcome_measure":"Incidence of CNS events by predictors","outcome_time_frame":"Up to 144 weeks","outcome_safety_issue":null}],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[],"secondary_outcomes":[{"outcome_description":"","outcome_measure":"Exposure adjusted incidence rate","outcome_time_frame":"Up to 144 weeks","outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":["N/A"]},"start_date":"05/26/2017 00:00:00","study_type":"Observational","therapeutic_area":"","citations":[],"is_section_801":null}},"pageContext":{"studyId":"207953"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}